211 related articles for article (PubMed ID: 35093840)
21. SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.
Di Filippo M; Ferraro D; Ragonese P; Prosperini L; Maniscalco GT; Gallo A; Cavalla P; Lorefice L; Nociti V; Di Sabatino E; Clerico M; Guaschino C; Radaelli M; Fantozzi R; Buttari F; Laroni A; Gajofatto A; Calabrese M; Malucchi S; Paolicelli D; De Luca G; Tomassini V; Lanzillo R; Moccia M; Solaro C; Cocco E; Gasperini C; Tortorella C;
J Neurol; 2024 Jan; 271(1):24-31. PubMed ID: 37922069
[TBL] [Abstract][Full Text] [Related]
22. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
[TBL] [Abstract][Full Text] [Related]
23. Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies.
Drulovic J; Ivanovic J; Martinovic V; Tamas O; Veselinovic N; Cujic D; Gnjatovic M; Mesaros S; Pekmezovic T
Mult Scler Relat Disord; 2021 Sep; 54():103150. PubMed ID: 34298478
[TBL] [Abstract][Full Text] [Related]
24. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
[TBL] [Abstract][Full Text] [Related]
25. Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination.
Asashima H; Kim D; Wang K; Lele N; Buitrago-Pocasangre NC; Lutz R; Cruz I; Raddassi K; Ruff WE; Racke MK; Wilson JE; Givens TS; Grifoni A; Weiskopf D; Sette A; Kleinstein SH; Montgomery RR; Shaw AC; Li F; Fan R; Hafler DA; Tomayko MM; Longbrake EE
JCI Insight; 2023 Aug; 8(16):. PubMed ID: 37606046
[TBL] [Abstract][Full Text] [Related]
26. Effects of MS disease-modifying therapies on responses to vaccinations: A review.
Ciotti JR; Valtcheva MV; Cross AH
Mult Scler Relat Disord; 2020 Oct; 45():102439. PubMed ID: 32769063
[TBL] [Abstract][Full Text] [Related]
27. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.
Ali H; Alterki A; Sindhu S; Alahmad B; Hammad M; Al-Sabah S; Alghounaim M; Jamal MH; Aldei A; Mairza MJ; Husain M; Deverajan S; Ahmad R; Cherian P; Alkhairi I; Alkandari A; Abubaker J; Abu-Farha M; Al-Mulla F
Front Immunol; 2021; 12():752233. PubMed ID: 34899701
[TBL] [Abstract][Full Text] [Related]
28. Vaccine hesitancy among people with multiple sclerosis.
Yap SM; Al Hinai M; Gaughan M; Callanan I; Kearney H; Tubridy N; McGuigan C
Mult Scler Relat Disord; 2021 Nov; 56():103236. PubMed ID: 34507240
[TBL] [Abstract][Full Text] [Related]
29. Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults.
Zhang Y; Yang Y; Qiao N; Wang X; Ding L; Zhu X; Liang Y; Han Z; Liu F; Zhang X; Yang X
Front Med; 2022 Feb; 16(1):93-101. PubMed ID: 35122211
[TBL] [Abstract][Full Text] [Related]
30. Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.
Marty PK; Van Keulen VP; Erskine CL; Shah M; Hummel A; Stachowitz M; Fatis S; Granger D; Block MS; Duarte-García A; Warrington KJ; Theel ES; Zhou X; Zeng H; Specks U; Escalante P; Peikert T
Front Immunol; 2022; 13():834981. PubMed ID: 35154159
[TBL] [Abstract][Full Text] [Related]
31. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations.
König M; Lorentzen ÅR; Torgauten HM; Tran TT; Schikora-Rustad S; Vaage EB; Mygland Å; Wergeland S; Aarseth J; Aaberge IAS; Torkildsen Ø; Holmøy T; Berge T; Myhr KM; Harbo HF; Andersen JT; Munthe LA; Søraas A; Celius EG; Vaage JT; Lund-Johansen F; Nygaard GO
J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):19-22. PubMed ID: 34670844
[TBL] [Abstract][Full Text] [Related]
32. Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects.
Maniscalco GT; Manzo V; Ferrara AL; Perrella A; Di Battista M; Salvatore S; Graziano D; Viola A; Amato G; Moreggia O; Di Giulio Cesare D; Barbato S; Servillo G; Longo K; Di Giovanni M; Scarpati B; Muggianu SM; Longo G; Russo G; Andreone V; De Rosa V
Mult Scler Relat Disord; 2022 Feb; 58():103455. PubMed ID: 34929455
[TBL] [Abstract][Full Text] [Related]
33. Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.
Achiron A; Mandel M; Gurevich M; Dreyer-Alster S; Magalashvili D; Sonis P; Dolev M; Menascu S; Harari G; Flechter S; Falb R
J Neurol; 2022 May; 269(5):2286-2292. PubMed ID: 35235002
[TBL] [Abstract][Full Text] [Related]
34. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.
Baker D; Roberts CAK; Pryce G; Kang AS; Marta M; Reyes S; Schmierer K; Giovannoni G; Amor S
Clin Exp Immunol; 2020 Nov; 202(2):149-161. PubMed ID: 32671831
[TBL] [Abstract][Full Text] [Related]
35. Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function.
Sabatino JJ; Mittl K; Rowles WM; McPolin K; Rajan JV; Laurie MT; Zamecnik CR; Dandekar R; Alvarenga BD; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Augusto DG; Alexander JR; DeRisi JL; Hollenbach JA; Wilson MR; Zamvil SS; Bove R
JCI Insight; 2022 Feb; 7(4):. PubMed ID: 35030101
[TBL] [Abstract][Full Text] [Related]
36. Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
Cohen JA; Bermel RA; Grossman CI; Hersh CM; Hyland M; Mowry EM; Naismith R; Naylor ML; Nicholas J; Rajbhandar R; Singh CM; Tintorè M; Zabalza A; Ziemssen T; Williams JR; Montalban X
Mult Scler; 2022 Jun; 28(7):1131-1137. PubMed ID: 34994577
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
38. Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.
Louapre C; Ibrahim M; Maillart E; Abdi B; Papeix C; Stankoff B; Dubessy AL; Bensa-Koscher C; Créange A; Chamekh Z; Lubetzki C; Marcelin AG; Corvol JC; Pourcher V;
J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):24-31. PubMed ID: 34341142
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
40. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
